AzTrials
AzTrials

Post Burn Facial HyperpigmentationPhase 2NCT07263841

Comparison of Effectiveness of Tranexamic Acid Mesotherapy Versus Glutathione Mesotherapy in Post Burn Facial Hyperpigmentation

A Phase 2 study testing Tranexamic Acid in people with Post Burn Facial Hyperpigmentation, run by King Edward Medical University at 1 site in Pakistan.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

INTERVENTION: Patch test on forearm will be performed in all patients before starting treatment to check the sensitivity. Site of burn in the enrolled patients will include either cheek or forehead and total area (cm2) on each of above mentioned sites will be divided into two equal halves; one for tranexamic acid… Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Post Burn Facial Hyperpigmentation
What is being tested?
Tranexamic Acid
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 sitePakistan
Study dates
1 Jun 2025to 26 Mar 2026
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Inclusion Criteria:● Both sexes of WHO adult age group 18-65 years .

  • Patients with healed facial burns managed conservatively without skin grafting.
  • From 6 month to 12 month post burn injury (patient enrollment to be done before scar maturation starts)
  • Patients with Fitzpatrick skin types III to IV.
  • Patients with mental capacity to give informed consent.

Exclusion Criteria:● Patients with documented hypersensitivity reactions to either drug or dressing etc.

  • History of de-pigmentation treatment, phototherapy.
  • Healed burn wounds with hypertrophic scar.
  • History of bleeding or clotting disorders, renal disease, collagen vascular disease and other photodermatoses3.
  • Pregnant or lactating females3.
  • Patients on hormone replacement therapy, oral contraceptives, concomitant use of anticoagulant, or any photosensitizing drug3.

Trial locations and contacts

1 site in 1 country.

Pakistan1 site
  • King Edward Medical University

    Lahore, Punjab Province, 54000

Other trials in Pakistan

About this study

INTERVENTION:

Patch test on forearm will be performed in all patients before starting treatment to check the sensitivity. Site of burn in the enrolled patients will include either cheek or forehead and total area (cm2) on each of above mentioned sites will be divided into two equal halves; one for tranexamic acid mesotherapy (maximum 5cm2) and other for glutathione mesotherapy (maximum 5cm2). Flip coin method will be used to decide which site and which half to be treated with tranexamic Acid or glutathione. Gentle cleansing of the affected area will be done Tranexamic acid is available in 500mg/5ml formulation, 1ml (100mg) of tranexamic acid will be taken and diluted in 10ml of 0.9% N/S i.e. 10mg/ml.This 10mg/ml of diluted formulation will be used for mesotherapy.

Read more

intradermally 1cm apart to the selected site using 1cc disposable syringe with 4mm depth 30G needle.4mm depth of intradermal injection will be controlled manually by the researcher on specific area of face. Maximum dose of tranexamic acid microinjections will not exceed 12.5 mg/5cm'.

Glutathione is available in 600mg powder formulation and will be prepared by dissolving in 5ml of distilled water. 1ml (120mg) of glutathione will be diluted in 10ml of 0.9% N/S i.e. 12mg/ml.This 12mg/ml of diluted formulation will be used for mesotherapy. Multiple microinjections, each 0.05ml (0.6mg) will be given intradermally 1cm apart to the selected site using 1cc disposable syringe with 4mm depth 30G needle. Maximum dose will not exceed 15mg/5cm2. All patients will be kept under observation for 20-30 minutes after each session to address any side effects (bruising, bleeding, pain etc.) and they will be advised to apply sunscreen of SPF 50 on whole of the face before sun exposure. After initial treatment session, patients will undergo six more treatment sessions with the same protocol at the interval of 2 weeks ( 2, 4, 6, 8, 10,12 weeks) and follow-up will be done monthly after the last session i.e. 4th, 5th and 6th month.

Final assessment will be done at 6th month. All clinical dermatoscopic photographs will be taken with Nikon D810 digital camera with dermlite 3 dermoscopy lens before the start of treatment, at each treatment session and then at each follow-up in same pre-settings, light and from same distance.

Read the detailed description

Burn injuries are one of the leading cause of morbidity and mortality especially in developing countries. skin pigmentation disorders are one of the most frequent sequelae after burn injury while these conditions often improve over time,some are permanent and cause severe psychological disorders(specially on the face). 1 Inflammation of burnt skin triggers the melanocytes during the healing process which results in overproduction of melanin pigment that subsequently either gets dispersed to the epidermal keratinocytes or gets engulfed by the newly recruited macrophages leading to epidermal and dermal melanosis respectively. Unfortunately skin types with darker complexion due to melanosis (Fitzpatrick type III to IV), common in the subcontinent, are more susceptible to post inflammatory hyperpigmentation.1,2 A myriad of treatments including topical bleaching agents, chemical peels, tretinoins, sunscreens and various lasers have been used to prevent and reduce the hyperpigmentation with suboptimal results.

Tranexamic acid (TXA) is a novel agent used in the treatment of post burn hyperpigmentation, available in topical, oral and parentral formulations.3,4 The drug is widely used as anti-fibrinolytic agent and exerts its effects by inhibiting plasminogen-keratinocyte interaction leading to decrease in activity of tyrosinase enzyme thereby resulting in decrease synthesis of melanin from melanocytes.3,4 Human keratinocytes secrete plasminogen activator, which increases the plasmin production and melanogenesis.5 Blockade of this effect is the mechanism behind the therapeutic effect of tranexamic acid.6,7 Tranexamic acid mesotherapy can be a very good option for treating patients of post burn hyperpigmentation.

Glutathione (GSH) is widely used drug available in topical, oral and parenteral formulations with indications encompassing hyperpigmentation, anti-aging and antioxidant effects.8 It improves skin pigmentation by shifting melanogenesis from eumelanin (black brown in color) to pheomelanin (yellow red in color) through inhibiting tyrosinase enzyme, thus regulating the rate limiting step in melanin production.8,9 Glutathione is present intracellularly more abundantly in the reduced form (GSH) and is readily converted into its oxidized form (GSSG) in the process of scavenging free oxygen redicals and other toxins while trying to maintain the redox balance of cellular environment, as described by Sidarth sonthalia in his study. 9 Consequently the levels of glutathione are found to be decreased in the tissues experiencing metabolic stress due to various inflammatory processes like burns and other diseases i.e allergies, melasma and malignancies. 8,9 In our study, we will use mesotherapy, which is an effective way of delivering de-pigmentation drugs like tranexamic acid and glutathione directly into the dermis which is the nidus of ongoing inflammatory process in the burn wounds while avoiding the undesirable consequences of systemic therapy.7,10 There is limited data about the regimen protocol and quantitative comparison of these two types of mesotherapies. This will be the first study on local and international level for measurement of post burn facial hyperpigmentation as to date there are no reliable objective methods for measuring skin hyperpigmentation quantitatively in this population of patients. Our study, with availability of ideal population sample from one of the largest burn centre in the country, will surely add to scarce knowledge currently published in literature regarding the use of tranexamic acid and glutathione to overcome hyperpigmentation. This can lower the psychosocial stigmata of post burn marks and ease the way of burn survivors for re-integration into society.

6.4 OBJECTIVE:

To compare the quantitative effectiveness of tranexamic acid mesotherapy versus glutathione mesotherapy in post burn facial hyperpigmentation.

6.5 OPERATIONAL DEFINITIONS: Post burn facial hyperpigmentation It is the condition of facial skin in which there is pigmentation of skin that follows the burn injuries i.e self-healed burns managed conservatively without skin grafting.

Mesotherapy Mesotherapy is a procedure in which multiple microinjections of tranexamic acid or glutathione will be given 1 cm apart for treating post burn facial hyperpigmentation.

Effectiveness

Effectiveness is the reduction in hyperpigmentation at 6 month follow-up and will be measured objectively as skin hyperpigmentation index (SHI) score using online digital processing system and SHI score ≤2 will be considered effective and graded as:

0-1 excellent responce 1-2 moderate response 2-3 mild response 3-4 no responce 6.6 HYPOTHESIS Tranexamic acid mesotherapy is more effective as compared to glutathione mesotherapy for reduction of pigmentation in post burn facial hyperpigmentation patients.

6.7 MATERIAL AND METHODS Study Design Randomized control trial. Setting Outpatient Department of Plastic surgery, King Edward medical University/ Mayo Hospital, Lahore.

Duration of Study Study will be completed within 6 months after approval of synopsis. Sample size Sample size of 60 patients is estimated by using 5% level of significance, 90% power of test with expected %age efficacy of tranexamic acid as 79% and of glutathione as 37.5% 10

  • Level of significance = 5% 1-β=Power of test 90% P1=%age excellent response with TA = 78% P2=%age excellent response with Glutathione = 37.5% n =60

Sampling Technique Non-probability convenient sampling

SELECTION CRITERIA:

Inclusion Criteria Both sexes of WHO adult age group 18-65 years . Patients with healed facial burns managed conservatively without skin grafting.

From 6 month to 12 month post burn injury (patient enrollment to be done before scar maturation starts) Patients with Fitzpatrick skin types III to IV. Patients with mental capacity to give informed consent. Exclusion Criteria Patients with documented hypersensitivity reactions to either drug or dressing etc.

History of de-pigmentation treatment, phototherapy. Healed burn wounds with hypertrophic scar. History of bleeding or clotting disorders, renal disease, collagen vascular disease and other photodermatoses3.

Pregnant or lactating females3. Patients on hormone replacement therapy, oral contraceptives, concomitant use of anticoagulant, or any photosensitizing drug3.

6.8 DATA COLLECTION PROCEDURE: Data will be collected using a pre-designed preform. Sixty patients (Fitzpatrick skin type III to IV) will be enrolled in this study. Patient's demographics and skin type will be noted. Written informed consent will be taken from the patients fulfilling the inclusion criteria from outpatient department of KEMU/ Mayo Hospital, Lahore.

PATIENT ASSESSMENT Patient will be assessed clinically at 2 weeks intervals using Skin hyperpigmentation index (SHI), which is a fully automated and standardized method for the quantitative assessment of skin pigmentation. Clinical photographs of pigmented and normal sun-protected unexposed area of body from same patient (L4 spinous process as reference point) will be uploaded in software to calculate skin hyperpigmentation index using following formula10 .

PSArea with hyperpigmentation SHI= __________________________ PSReference point

PS =skin pigmentation

SHI score will be graded as:

0-1= No hyperpigmentation: Excellent response 1-2= Light hyperpigmentation: Moderate response 2-3= Medium hyperpigmentation: Mild response 3-4= Severe hyperpigmentation: No response

.

6.9 DATA ANALYSIS PROCEDURE: Data will be entered and analyzed by using SPSS 26 (IBM SPSS statistics for windows, version 26.0 NY: IBM corp). Quantitative variables like SHI score will be presented as mean and standard deviation. Qualitative variables like gender will be presented as frequency and percentages and analysed by chi-square. For Comparison of effectiveness of tranexamic acid mesotherapy and glutathione mesotherapy we will apply sample t-test if normally distributed. P value <0.05 will be considered significant.

6.10 OUTCOME \& UTILIZATION: Post burn facial hyperpigmentation is a very common problem especially in women. Its management is challenging because it runs a chronic course producing significant emotional and psychological effects in patients. There is limited efficacy of oral and local treatments and they require prolonged usage which leads to disappointment in patients. So, we have designed a study in which tranexamic acid mesotherapy and glutathione mesotherapy will be done in such patients and effectiveness of both will be compared quantitatively. Also, it will be the first study in Pakistan on quantitative comparison of tranexamic acid and glutathione mesotherapy in post burn hyperpigmentation. Perhaps in the near future, one of the studied options will be considered potentially efficacious and safe in the treatment of post burn facial hyperpigmentation. This will help to implement a better management of facial hyperpigmentation in burn patients to improve their quality of life and social integration.

Being tested
Tranexamic Acid
Keywords
hyperpigmentation, Mesotherapy, Effectiveness
Medical subject headings
Hyperpigmentation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tranexamic AcidDrug

    Also called glutathione

    tranexamic acid decreases melanogenesis by inhibiting tyrosinase enzyme while glutathione converts eumelanin to pheomelanin

Study groups in NCT07263841
Study groupRoleWhat they receive
fitzpatrick skin type3,4 patients of post burn facial hyperpigmentation will be included in this armExperimentalfacial hyperpigmentation lesion will be divided into 2 halves and one treatment will be administered on each half
Receives: Drug: Tranexamic Acid

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. improvement in facial hyperpigmentation

    patients will be assessed for improvement in hyperpigmentation by skin hyperpigmentation index till 6 months after completion of sessions

    Measured: 6months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Dec 2025
  2. Study start1 Jun 2025
  3. Primary completion26 Dec 2025 (estimated)
  4. Study completion26 Mar 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
each patient will be given both treatments, every participant will act as his own control.
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07263841
Sponsor's protocol ID
435/RC/KEMU
Status last verified
Nov 2025
First submitted
23 Nov 2025
Last updated
4 Dec 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: privacy concerns of patient

Publications

  • Isseroff RR, Rifkin DB. Plasminogen is present in the basal layer of the epidermis. J Invest Dermatol. 1983 Apr;80(4):297-9. doi: 10.1111/1523-1747.ep12534677.

    PubMed 6339645

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Tranexamic Acid in people with Post Burn Facial Hyperpigmentation, run by King Edward Medical University at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 4 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

improvement in facial hyperpigmentation (time frame: 6months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07263841, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in